KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Liabilities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Total Liabilities for 13 consecutive years, with $51.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 18.89% to $51.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $51.4 million, a 18.89% increase, with the full-year FY2025 number at $51.4 million, up 18.89% from a year prior.
  • Total Liabilities was $51.4 million for Q4 2025 at Xenon Pharmaceuticals, up from $48.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $51.4 million in Q4 2025 to a low of $14.4 million in Q1 2021.
  • A 5-year average of $31.9 million and a median of $33.7 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: crashed 70.66% in 2021, then surged 103.16% in 2023.
  • Xenon Pharmaceuticals' Total Liabilities stood at $22.0 million in 2021, then surged by 48.58% to $32.6 million in 2022, then grew by 12.95% to $36.9 million in 2023, then rose by 17.24% to $43.2 million in 2024, then rose by 18.89% to $51.4 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Total Liabilities are $51.4 million (Q4 2025), $48.3 million (Q3 2025), and $40.3 million (Q2 2025).